Neuralstem Reports Second Quarter 2019 Fiscal Results

Neuralstem Announces Nasdaq Hearings Panel Grants Request For Continued Listing

Neuralstem Closes $7.5 Million Underwritten Public Offering

Neuralstem Announces Pricing of $7.5 Million Underwritten Public Offering

Neuralstem Appoints Mary Ann Gray, Ph.D., to Board of Directors

Neuralstem Announces a 1-for-20 Reverse Stock Split

Neuralstem Announces Publication of Results from Phase 1 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients

Neuralstem Announces Issuance of New Patent Covering Broad Therapeutic Use of Neural Stem Cells

Neuralstem Reports First Quarter 2019 Fiscal Results

Neuralstem Appoints David J. Mazzo, Ph.D., to Board of Directors